Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer detected by PSMA.
To be considered for the study you must meet the following criteria:
- aged 18+
- Confirmed prostate adenocarcinoma with castration-resistance
- Baseline PSA of at least 2ng/ml, PSA doubling time of 10 months or less and at least 2 consecutive rises
Darolutamide is a drug that has a proven survival benefit in non-metastatic (M0) castrate resistant prostate cancer when using conventional imaging. However, it is estimated that >90% of patients have disease apparent whenusing PSMA PET. This study investigates the use of local consolidation radiotherapy in this cohort of men.